Plain-English translation of NCT07082738 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a 24-week study testing whether a new medication called can help people with moderate to very severe COPD (a chronic lung disease that makes breathing difficult). About 970 people will take part, with some receiving the medication at one of two different doses and others receiving a placebo (a fake pill) to see which works best. Researchers want to find out if this treatment can reduce breathing problems and prevent flare-ups of the disease.
COPD is a serious lung disease that gets worse over time, and current treatments don't work well enough for everyone. This trial exists to see if this medication can offer better relief and help people avoid sudden flare-ups that require hospital visits.
You likely qualify if…
You likely don't qualify if…
You will visit the study site multiple times over 24 weeks. At the start, you'll have tests to confirm your COPD diagnosis and get a baseline measurement of how well your lungs work. You'll then be randomly assigned to take either the new medication at one of two doses or a placebo pill once daily. Throughout the study, you'll have follow-up visits where doctors will monitor your lung function, check how many flare-ups you've had, and watch for any side effects.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
United States